For years, Cassava Sciences stock was one of the most polarizing and highly watched equities on the Nasdaq. Under its iconic ticker symbol SAVA, this clinical-stage biopharmaceutical firm was the ultimate "battleground stock" in the retail investing community. Bulls envisioned a historic breakthrough in the treatment of Alzheimer’s disease with its lead drug candidate, simufilam. Bears, on the other hand, pointed to persistent allegations of data manipulation, regulatory scrutiny, and corporate misconduct.
Fast forward to mid-2026, and the landscape has shifted completely. SAVA is no longer trading under its original name, the Alzheimer’s clinical program has been permanently dismantled, and the company has executed a drastic corporate pivot. If you are searching for Cassava Sciences stock today, you are looking at a transformed entity known as Filana Therapeutics, Inc. (NASDAQ: FLNA).
In this comprehensive analysis, we will dive deep into the dramatic fall of the SAVA ticker, break down the results of the Phase 3 clinical trials, analyze the legal and regulatory resolutions, examine the company’s pivot to epilepsy, and evaluate the financial prospects of the newly minted FLNA stock.
Chronology of a Collapse: SAVA's Failed Alzheimer's Ambitions
To understand the current state of Cassava Sciences stock, one must trace the clinical trials that ultimately sealed the fate of its Alzheimer's disease program. Simufilam (formerly known as PTI-125) was developed as an oral small molecule designed to bind to a misfolded form of the scaffolding protein filamin A (FLNA). The therapeutic hypothesis was that restoring altered filamin A to its normal shape and function would disrupt pathogenic signaling cascades in the brain, thereby reducing both neuroinflammation and tau hyperphosphorylation.
While early open-label data generated massive enthusiasm—driving SAVA stock above $135 a share at its speculative peak in 2021—the ultimate proof lay in two rigorous, double-blind, placebo-controlled Phase 3 clinical trials: RETHINK-ALZ and REFOCUS-ALZ.
RETHINK-ALZ and REFOCUS-ALZ Results
- RETHINK-ALZ (NCT04994483): This trial randomized 804 participants with mild-to-moderate Alzheimer’s disease to receive either simufilam 100 mg or a placebo daily for 52 weeks. In November 2024, Cassava reported topline results: the drug completely failed to meet its co-primary endpoints of cognitive improvement (measured by the ADAS-Cog12 scale) and functional decline (measured by the ADCS-ADL scale). There were no statistically significant differences between the simufilam group and the placebo group.
- REFOCUS-ALZ (NCT05026177): Enrolling 1,125 participants, this longer 76-week study was designed to evaluate both 50 mg and 100 mg doses of simufilam against a placebo. Following the disastrous RETHINK results, Cassava discontinued the trial in March 2025. Topline analyses confirmed that, like its sister study, REFOCUS-ALZ showed no clinical benefit over placebo across the co-primary, secondary, or biomarker endpoints.
The Final Scientific Verdict (JPAD Publication)
In January 2026, the company published a detailed, peer-reviewed analysis of both trials in the Journal of Prevention of Alzheimer's Disease (JPAD). While the paper confirmed simufilam's favorable safety profile, it solidified the reality that the drug did not work for mild-to-moderate Alzheimer's disease.
One critical post-hoc finding revealed that approximately 21% of the participants in a REFOCUS-ALZ amyloid PET sub-study were unexpectedly amyloid-negative at baseline. This meant they did not actually have the classic pathology of Alzheimer's disease, highlighting a major limitation in the trial's enrollment screening criteria which relied on plasma p-tau181 rather than expensive PET scans. Regardless of the retrospective lessons for the scientific community, the business outcome was definitive: Cassava announced it had discontinued all investment in its Alzheimer's disease program.
Scandal, Lawsuits, and Settlements: Cleaning Up the Baggage
Before Cassava Sciences stock could move forward, the company had to settle a mount of legal, regulatory, and criminal liabilities that had accumulated over years of heated debate. The controversy began in August 2021 when a citizen's petition filed with the FDA alleged that foundational scientific data in papers authored by Cassava's academic advisor, Dr. Hoau-Yan Wang, had been manipulated.
What followed was a slow-motion corporate unraveling:
- Executive Resignations (July 2024): Amidst expanding federal scrutiny, founder and long-time CEO Remi Barbier resigned, along with his wife, Lindsay Burns, who had served as Senior Vice President of Neuroscience. Board member Rick Barry stepped in as President and interim CEO, later taking on the role permanently.
- SEC Fraud Charges and Fines (September 2024): The U.S. Securities and Exchange Commission (SEC) charged Cassava, Barbier, Burns, and Dr. Wang with making misleading statements regarding the results of a 2020 Phase 2 clinical trial. Without admitting or denying the allegations, the parties settled. Cassava agreed to pay a $40 million civil penalty, while Barbier, Burns, and Wang agreed to individual penalties of $175,000, $85,000, and $50,000, respectively.
- Class-Action Litigation Settlement (December 2025): Cassava finalized a settlement agreement to resolve long-standing securities class-action lawsuits brought by disgruntled shareholders who accused the company of artificially inflating its stock price.
- The Closure of the DOJ Investigation (February 2026): In a massive sigh of relief for the surviving corporate structure, the U.S. Department of Justice (DOJ) closed its criminal investigation into Cassava Sciences without filing charges against the company itself. Furthermore, criminal fraud charges against Dr. Wang were abruptly dropped by federal prosecutors in late 2025 shortly before trial.
By early 2026, the company had successfully cut its legal ties to its highly controversial past. However, the cost of these settlements and the failed clinical trials had thoroughly drained its balance sheet and crippled the original brand.
The Rebrand: Meet Filana Therapeutics (NASDAQ: FLNA)
With its legal battles largely resolved and its Alzheimer's program buried, the company's leadership recognized that the "Cassava Sciences" brand was too damaged to salvage.
On March 10, 2026, the company announced a complete rebranding. Cassava Sciences, Inc. officially changed its name to Filana Therapeutics, Inc.. Along with the name change, the company retired its legendary "SAVA" ticker symbol, transitioning to trade under the symbol FLNA on the Nasdaq Capital Market effective March 11, 2026.
+----------------------------+
| CASSAVA SCIENCES (SAVA) |
+--------------+-------------+
|
Failed Phase 3 ALZ Trials
SEC & Class-Action Settlements
DOJ Case Closed
|
v
+----------------------------+
| FILANA THERAPEUTICS (FLNA) |
+--------------+-------------+
|
Pivoted to TSC Epilepsy
FDA Clinical Hold Resolution
Restructured Leadership
According to CEO Rick Barry, the name Filana was chosen to align the corporate identity with its scientific core: the modulation of the filamin A (FLNA) protein. The rebrand was positioned as a "new beginning" to shed the baggage of historical scandals and focus on a completely different therapeutic target.
SAVA vs. FLNA: A Quick Comparison
| Feature | Cassava Sciences (SAVA) Era | Filana Therapeutics (FLNA) Era |
|---|---|---|
| NASDAQ Ticker | SAVA | FLNA |
| Primary Drug Candidate | Simufilam | Simufilam |
| Lead Disease Indication | Mild-to-moderate Alzheimer's disease | Tuberous Sclerosis Complex (TSC)-related epilepsy |
| Key Executive Leadership | Remi Barbier (Founder/CEO) | Rick Barry (President & CEO) |
| Clinical Focus | Phase 3 Trials (Failed) | Phase 2 / Proof-of-Concept (FDA Clinical Hold) |
| Legal/Regulatory Status | Under SEC/DOJ active investigation | Investigations closed, civil lawsuits settled |
The Epilepsy Pivot: Can Simufilam Find a Second Life?
Filana Therapeutics is betting its entire future on a single pivot: repurposing simufilam to treat Tuberous Sclerosis Complex (TSC)-related epilepsy.
The Science Behind TSC-Related Epilepsy
TSC is a rare genetic disorder caused by mutations in either the TSC1 or TSC2 gene. These mutations lead to overactivation of the mechanistic target of rapamycin (mTOR) pathway, resulting in non-cancerous tumors growing throughout various organs, particularly the brain. Epilepsy is the single most common health complication affecting individuals with TSC, with up to 90% of patients experiencing severe, drug-resistant seizures. TSC-related epilepsy affects approximately 45,000 people in the United States alone.
Preclinical research conducted in the laboratory of Dr. Angélique Bordey at the Yale School of Medicine suggests that filamin A plays an important role in neuronal development under TSC-related pathology. In mouse models of focal-onset seizures, treatment with simufilam was shown to reduce seizure frequency by 60% compared to a placebo control. Furthermore, studies conducted in conjunction with the TSC Alliance's Preclinical Consortium showed a dose-dependent reduction in seizure activity progression.
The Current Hurdle: FDA Clinical Hold
While the preclinical data is promising, Filana Therapeutics faces a critical near-term obstacle. In December 2025, the U.S. Food and Drug Administration (FDA) placed a full clinical hold on the company's planned Phase 2 proof-of-concept trial in TSC-related epilepsy.
According to corporate disclosures, the FDA requested additional detailed information regarding patient risk assessments and safety protocols before allowing clinical dosing to begin. As a result, Filana had to delay the initiation of the study, which was originally scheduled for the first half of 2026. Responding to and resolving this FDA clinical hold is currently the most significant catalyst for FLNA stock.
Financial Analysis: Is FLNA Stock a Highly Speculative Buy?
Following the rebranding and ticker transition, FLNA is trading as a micro-cap biotechnology stock in the $1.15 to $1.30 range, reflecting a massive loss of value from SAVA's historic levels. The company's market capitalization has shrunk to approximately $60 million.
The Bear Case: Extreme Capital Depletion
- Heavy Cash Burn: Filana is operating in survival mode. According to financial reports for the trailing twelve months, the company suffered a net loss of over $106 million. Given its clinical failures and SEC settlement expenses ($40 million paid in late 2024), its cash reserves have been severely depleted.
- Single-Asset Dependency: Filana is a one-trick pony. The entire investment thesis rests on simufilam. If the FDA does not lift the clinical hold on the epilepsy trial, or if future clinical data replicates the disappointing results of the Alzheimer's trials, the stock could head toward zero.
- Dilution Risk: To fund any future trials for TSC-related epilepsy, Filana will inevitably need to raise capital. Given its low stock price, any equity offering will result in severe dilution for existing shareholders.
The Bull Case: Hidden Value and Rebound Potential
- Low Valuation: At a $60 million market cap, much of the historic negativity is priced in. If the company successfully resolves the FDA clinical hold and reports positive preliminary safety or efficacy data in its epilepsy program, the stock could experience a massive percentage-based recovery.
- Institutional Backing: Despite the turmoil, some institutional investors and hedge funds (such as Marshall Wace LLP) have maintained or initiated speculative positions, betting on a turnaround under new management.
- Simplified Corporate Structure: The closure of the DOJ investigation and the finalization of the class-action settlements remove the "legal overhang" that made SAVA uninvestable for many traditional biotech funds.
The Consensus: A High-Risk Penny Stock
Wall Street analysts have largely abandoned coverage of the stock. The remaining analysts hold a consensus "Hold" or "Speculative Buy" rating with highly conservative, single-digit price targets (averaging around $5.00 to $8.00), representing a far cry from the triple-digit valuations of SAVA's past.
Investors must view FLNA as a highly speculative, high-risk micro-cap play. It is only suitable for those with an extremely high risk tolerance who are comfortable with the volatile dynamics of clinical-stage biotech penny stocks.
Frequently Asked Questions (FAQ)
What happened to Cassava Sciences (SAVA) stock?
On March 10, 2026, Cassava Sciences rebranded as Filana Therapeutics, Inc. The company changed its Nasdaq ticker symbol from SAVA to FLNA, effective March 11, 2026.
Is Simufilam still being developed for Alzheimer’s disease?
No. Following the clear clinical failures of the Phase 3 RETHINK-ALZ and REFOCUS-ALZ trials—which did not show efficacy on co-primary, secondary, or biomarker endpoints—the company terminated all development of simufilam for Alzheimer's disease.
Did the government find Cassava Sciences guilty of scientific fraud?
The U.S. Department of Justice (DOJ) closed its criminal investigation into Cassava Sciences in February 2026 without bringing charges against the company. Separately, criminal charges against corporate advisor Dr. Hoau-Yan Wang were dropped in late 2025. However, the company paid a $40 million penalty to the SEC in 2024 to settle civil charges of making misleading statement without admitting or denying wrongdoing.
What is Filana Therapeutics’ new focus?
Filana is focusing on utilizing simufilam to treat Tuberous Sclerosis Complex (TSC)-related epilepsy. Preclinical animal models demonstrated a significant 60% reduction in seizure frequency, but clinical trials are currently delayed due to an FDA clinical hold.
Is FLNA stock a good investment?
FLNA is an extremely high-risk, speculative penny stock. While it has shed its regulatory investigations and legal liabilities, the company is burning through cash and its sole asset is subject to an active FDA clinical hold. Only risk-tolerant investors should consider trading it.
Conclusion: Navigating the New Era of Filana Therapeutics
The story of Cassava Sciences stock is a cautionary tale of the extreme volatility, intense speculation, and scientific uncertainty that defines the biotechnology sector. From its peak as a $100+ retail market darling to its fall into single-digit penny stock territory, SAVA has experienced a complete metamorphosis.
Now trading as Filana Therapeutics (FLNA), the company has cleared its legal desk by settling lawsuits and seeing federal investigations closed. However, the clinical task ahead is steep. To reward shareholders, Filana must first satisfy the FDA to lift the clinical hold on its epilepsy program and then prove that simufilam's mechanism actually translates to seizure reduction in humans.
For investors, the SAVA chapter is officially closed, and the high-stakes, highly speculative FLNA chapter has just begun.
